Richard Kahr - Pacira BioSciences, Vice Resources
| PCRX Stock | USD 16.64 0.14 0.83% |
Executive
Richard Kahr is Vice Resources of Pacira BioSciences,
| Address | 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 |
| Phone | 813 553 6680 |
| Web | https://www.pacira.com |
Pacira BioSciences, Management Efficiency
The company has return on total asset (ROA) of 0.0417 % which means that it generated a profit of $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1148) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Archana Bhaskar | Dr Reddys Laboratories | 53 | |
| YUGANDHAR PUVVALA | Dr Reddys Laboratories | 48 | |
| Selina Zhang | HUTCHMED DRC | N/A | |
| Anil Namboodiripad | Dr Reddys Laboratories | 54 | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Stephen Schiavo | Alkermes Plc | N/A | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Jayanth Sridhar | Dr Reddys Laboratories | 53 | |
| Kin MBA | HUTCHMED DRC | 47 | |
| Christine CPA | Prestige Brand Holdings | 48 | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Larry Miller | Phibro Animal Health | 60 | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| SANJAY SHARMA | Dr Reddys Laboratories | 52 | |
| Christopher Mutz | ANI Pharmaceuticals | 53 | |
| Mannam Venkatanarasimham | Dr Reddys Laboratories | N/A | |
| Sumera Hasham | Dr Reddys Laboratories | N/A | |
| Sushrut Kulkarni | Dr Reddys Laboratories | 54 | |
| Qingmei Wang | HUTCHMED DRC | 61 | |
| David Ng | HUTCHMED DRC | N/A | |
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0417 |
Pacira BioSciences, Leadership Team
Elected by the shareholders, the Pacira BioSciences,'s board of directors comprises two types of representatives: Pacira BioSciences, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pacira. The board's role is to monitor Pacira BioSciences,'s management team and ensure that shareholders' interests are well served. Pacira BioSciences,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pacira BioSciences,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Kahr, Vice Resources | ||
| Daryl Gaugler, Chief Officer | ||
| Charles Laranjeira, Chief Technical Officer | ||
| Christopher Young, Chief Officer | ||
| Shawn Cross, Chief Officer | ||
| DO Ellis, Chief Officer | ||
| III CPA, Chief Officer | ||
| Max Reinhardt, Pres World | ||
| Dennis McLoughlin, Chief Commercial Officer | ||
| David Stack, Chairman and CEO | ||
| Kristen JD, Chief Secretary | ||
| Roy MD, Chief Officer | ||
| Susan Mesco, IR Contact Officer | ||
| Jonathan MD, Chief Officer | ||
| Lauren Riker, Principal Finance | ||
| Frank Lee, CEO Director | ||
| Esq III, Chief Officer |
Pacira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pacira BioSciences, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0417 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 994.95 M | ||||
| Shares Outstanding | 46.17 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 5.46 M | ||||
| Price To Earning | 14.34 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.